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Abbreviations 
 
MA    Mucinous cystadenoma 
MBT    Mucinous borderline tumors 
IMBT    Intestinal- type mucinous borderline tumors 
EMBT   Endocervical- type mucinous borderline tumors 
SBT    Serous borderline tumor 
MCa    Mucinous adenocarcinoma 
IMCa    Intestinal type mucinous adenocarcinoma 
EMCa    Endometrioid adenocarcinoma 
CCCa    Clear cell adenocarcinoma 
HGSCa   High grade serous carcinoma 
LGSCa   Low grade serous carcinoma 
CRC    Colorectal carcinoma 
BT    Brenner tumor 
IC    Inclusion cyst 
EC    Endometrial cyst 
MCT    Mature cystic teratoma 
SCA    Serous cystadenoma 
TMA    Tissue micro array 
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Abstract  
Ovarian mucinous tumors are generally classified into mucinous 
cystadenoma (MA), mucinous borderline tumors (MBTs) and mucinous 
adenocarcinoma (MCa). MBTs are subclassified into intestinal-type (IMBTs) and 
endocervical-like (EMBTs) tumors. Almost all MCas are considered to be of 
intestinal-type (IMCa). In this study we attempted to clarify the phenotypes, and 
direction of differentiation of mucinous epithelium that constitutes MA, MBTs 
and MCas by immunohistochemistry. A panel of antibodies that included gastric 
markers (claudin-18 [CLDN18], MUC5AC, and MUC6), intestinal markers 
(MUC2 and CDX2), Müllerian markers (ER, PgR, CA125, and vimentin), and 
cytokeratins (CK7 and CK20) was applied. Special attention was paid to the 
expression of CLDN18, which is a recently established gastric marker.  
The results of this study showed that intestinal-type, and endocervical-like 
ovarian mucinous tumors are two distinct entities with completely different 
immunophenotype. Frequent and diffuse expression of gastric markers, along 
with less frequent and usually focal expression of intestinal markers in IMBTs 
and IMCas, suggested that these lesions, which have conventionally been 
regarded as “intestinal-type” are essentially of “gastrointestinal-type”. In addition, 
we showed that CLDN18 can serve as a useful diagnostic marker for IMBTs and 
IMCas, because EMBTs, ovarian non-mucinous adenocarcinomas and metastatic 
colorectal carcinomas involving the ovaries were CLDN18-negative. Lastly, we 
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found that most MAs are also of gastrointestinal-type. Coexistence of mature 
cystic teratoma, Brenner tumor and estrogen-receptor-positive Müllerian-type 
epithelium such as that of endometrial cyst were observed in a subset of MAs 
with gastrointestinal-type phenotype. Therefore, these coexistent lesions are 
candidate for the origin of gastrointestinal-type mucinous tumors.  
 
 
General Introduction: 
The author came to Japan from Afghanistan 5 years ago with a mission to 
study surgical pathology in Japan, and become the first practicing surgical 
pathologist in Afghanistan. While, being trained for diagnostic surgical 
pathology at the Department of Pathology of the University of Tokyo Hospital, 
the author began to have strong interest in gynecological pathology, especially in 
pathology of ovarian tumors. This thesis encompasses results of the 
comprehensive histological and immunohistochemical study performed on 
ovarian mucinous tumors. Every single case of ovarian mucinous tumor 
diagnosed at the University of Tokyo Hospital in the past 26 years is included in 
this study. As a consequence, this is one of the largest pathological studies 
performed to date regarding ovarian mucinous tumors. 
Mucinous tumor is one of the major histological subtypes of ovarian 
epithelial neoplasms along with other subtypes (serous, clear cell and 
endometrioid tumors). In recent 10 years, significant advances were made in the 
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research field of non-mucinous ovarian tumors. For example, as for serous 
adenocarcinomas, their origin was shown to be fallopian tube epithelium. Further, 
almost all of them were proved to harbor TP53 mutations. (1, 2) In clear cell and 
endometrioid adenocarcinomas, their association with endometriosis and 
involvement of ARID1A mutations were revealed (3). With regards to ovarian 
mucinous tumors, however, much about their origin and pathogenesis remain 
unclear. In this study, we tried to investigate the pathobiology of ovarian 
mucinous tumors from histological and immunohistochemical points of view. 
According to the current WHO classification, mucinous tumors have been 
classified into mucinous cystadenoma (MA), mucinous borderline tumors (MBT), 
and mucinous adenocarcinoma (MCa). Around 80% of these tumors are benign 
or cystadenomas. The remainders are mucinous borderline tumor (MBT), 
noninvasive (intraepithelial or intraglandular) mucinous adenocarcinomas, and 
invasive mucinous adenocarcinoma. MBTs are subclassified into intestinal-type 
(IMBTs), and endocervical-like (EMBTs) tumors. In intestinal-type tumors, the 
epithelium is tall columnar in appearance and have small basal nuclei with 
intracytoplasmic mucin. Their epithelium is most often similar to 
gastrointestinal-tract epithelium such as gastric foveolar and pyloric-type 
epithelium, or intestinal-type epithelium with scattered goblet cells. In 
endocervical-like tumors, the epithelium is usually composed of tall columnar 
cells with intracytoplasmic mucin which show ciliated change on the surface. No 
goblet cells are found. They show some resemblance to normal uterine cervical 
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glandular epithelium. Almost all MCas are considered to be of intestinal-type 
(IMCa), and they are supposed to develop in a stepwise manner, from MA to 
IMBT and to IMCa. Endocervical-like mucinous adenocarcinomas are extremely 
rare. From diagnostic stand points, distinction between IMCas and metastatic 
colorectal carcinomas is often difficult. But it is critical in patient’s management. 
As for MAs, subclassification such as intestinal-type and endocervical-type has 
not been clearly defined at this point, since the characteristics of their epithelium 
have not been evaluated in detail. 
In this study, we performed comprehensive histopathological and 
immunohistochemical analysis of ovarian mucinous tumors. We analyzed 
consecutive ovarian mucinous tumors that were surgically removed at the 
University of Tokyo Hospital, including MAs, MBTs, and MCas, by 
immunohistochemistry. In addition a variety of benign and metaplastic ovarian 
mucinous lesions, non-mucinous and Müllerian duct derivatives were also 
analyzed.  
This thesis comprise of three independent studies:  
In the first part, we analyzed the phenotypes and directions of 
differentiation of the mucinous epithelium in mucinous borderline tumor by 
immunohistochemistry. The main purpose of this study was to elucidate the 
difference between intestinal-type, and endocervical-like mucinous tumors. Since, 
histological distinctions between the two subtypes are established more clearly in 
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borderline tumors than in carcinomas/adenomas, we focused specially in 
borderline tumors to start the first part of this thesis study. A panel of antibodies 
that included gastric markers (claudin-18 [CLDN18], MUC5AC, and MUC6), 
intestinal markers (MUC2 and CDX2), Müllerian markers (ER, PgR, CA125, and 
vimentin), and cytokeratins (CK7 and CK20) has been applied. In this study, 
special attention was paid on the expression of CLDN18, one of the claudins that 
constitutes a family of 27 proteins essential for the formation of tight junctions, 
and the maintenance of polarity in epithelial, and endothelial cells. 
In the second parts, we attempted to investigate the expression of 
CLDN18 in various subtypes of ovarian adenocarcinomas. Since, intestinal-type 
mucinous adenocarcinoma was suspected to have gastric phenotype from 
morphological evaluation, we tried to confirm that by applying CLDN18 
immunohistochemistry. We then, assessed the utility of CLDN18 
immunohistochemistry in differentiating intestinal-type mucinous 
adenocarcinoma (IMCas) and other subtypes of non-mucinous ovarian 
adenocarcinomas, as well as metastatic colorectal adenocarcinomas (CRCs) 
involving the ovaries. 
Lastly, we analyzed a series of mucinous cystadenomas 
immunohistochemically, using gastric, intestinal, and Müllerian markers. Our 
aim was to elucidate the direction of the differentiation of mucinous epithelium 
that arises in the ovary and to seek for a possible histogenetic linkage between 
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gastrointestinal and Müllerian-type epithelium in the ovary. CLDN18 
immunohistochemistry was also performed in variety of benign and metaplastic 
mucinous lesions and Müllerian duct derivatives to determine, candidate lesions 
those can give rise to benign gastric-type mucinous epithelium in the ovary, 
which we have shown to be CLDN18 positive. 
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Claudin-18 overexpression in intestinal-type mutinous 
borderline tumor of the ovary 
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Background 
According to the current classification of the World Health Organization 
(WHO), ovarian mucinous borderline tumors (MBTs) are further classified into 
two types: intestinal-type mucinous borderline tumors (IMBTs) and 
endocervical-like mucinous borderline tumors (EMBTs)(4).   
These tumors have been given a variety of names in the past literature, and 
there is certain confusion with regard to their nomenclature. Some authors refer 
to IMBTs as “gastrointestinal”-type mucinous borderline tumors (5-8). Terms 
such as “seromucinous,” “Müllerian-type,” and “non-gastrointestinal type” are 
frequently used to refer to EMBTs (5, 6, 8-12). The inconsistency in 
nomenclature is primarily due to the subjective interpretation of the 
morphological features of IMBTs and EMBTs by each author. Paucity of the 
objective data regarding the phenotypes and direction of differentiation of the 
mucinous epithelium of IMBTs and EMBTs is another reason. 
Distinction between IMBTs and EMBTs is important because their 
clinicopathological features differ significantly (5, 6, 10, 12-14). IMBTs 
comprise approximately 85% of MBTs. They are usually unilateral (over 90%) 
(13). Most IMBTs are large multicystic masses, and their epithelial component 
has been described as a mixture of intestinal-type, gastric-type, and endocervical-
type mucinous epithelium that grows predominantly in glandular or cystic 
structures admixed with papillary and villous structures (10, 12, 13). Although 
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intestinal differentiation, which is represented by the presence of goblet cells and 
CDX2 immunoreactivity, has been regarded as a key feature of IMBTs (5, 10, 12, 
13, 15) mucinous epithelium that resembles gastric foveolar-type epithelium is 
often the predominant component of IMBTs in our observations and in 
observations by others (5, 16). In fact, Ji et al. reported frequent expression of 
MUC5AC, a gastric foveolar epithelial marker, in IMBTs (17). The tumor cells 
of IMBTs show a variable degree (mild to moderate) of atypia, and coexistence 
of a benign-looking mucinous cystadenoma component is often observed. It is 
generally accepted that stepwise malignant transformation occurs from MA to 
IMBT and to usual type (non-endocervical type) intestinal-type mucinous 
adenocarcinoma (IMCa). However, the precise origin of these tumors remains 
unclear. 
Compared with IMBTs, EMBTs are much less common and smaller, and 
they tend to occur in younger females (18-20). EMBTs are more frequently 
bilateral, and they show a paucilocular gross appearance with intracystic 
papillary projection (14, 20). Histologically, EMBTs are characterized by finely 
branching papillae with fibrovascular cores, and their architecture closely 
resembles that of serous borderline tumors (SBTs). The lining epithelium is 
composed of columnar mucin-containing cells and indifferent polygonal cells 
with eosinophilic cytoplasm (12, 14, 21). The former resemble endocervical cells. 
However, the glandular epithelium of EMBTs does not necessarily resemble that 
of typical endocervical glands because the above two types of cells are usually 
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admixed with each other, and cellular tufting and budding are prominent. Goblet 
cells are rarely found in EMBTs (12, 19, 20). EMBTs are frequently associated 
with endometriosis, (18, 19, 22) and they share common immunohistochemical 
features with SBTs and low-grade endometrioid carcinomas, such as positivity 
for estrogen receptor [ER] and progesterone receptor [PgR], suggesting the 
Müllerian nature of the neoplasm (5, 6, 8, 11). 
 
Study aims 
We herein attempted to clarify the phenotypes and directions of 
differentiation of the mucinous epithelium that constitutes IMBTs and EMBTs by 
immunohistochemical analysis. A panel of antibodies that included gastric 
markers (claudin-18 [CLDN18], MUC5AC, and MUC6), intestinal markers 
(MUC2 and CDX2), Müllerian markers (ER, PgR, CA125, and vimentin), and 
cytokeratins (CK7 and CK20) was applied. The expression of these markers was 
also assessed in SBTs to reveal the typical phenotype of Müllerian-type tumors. 
In this study, special attention was paid to the expression of CLDN18, which is a 
recently established gastric marker. CLDN18 is one of the claudins that 
constitutes a family of 27 proteins essential for the formation of tight junctions 
and the maintenance of polarity in epithelial and endothelial cells (23, 24). 
Positive immunoreactivity for CLDN18 has been shown in all types of gastric 
epithelium (foveolar-type, pyloric-type, and fundic-type) (25, 26). Thus, we 
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believe that CLDN18 is one of the best pan-gastric immunohistochemical 
markers available at this time. 
 
Materials and methods 
Tissue samples 
A total of 79 ovarian MBTs (54 IMBTs and 25 EMBTs) from 75 patients 
were retrieved from the archives of the Department of Pathology of the 
University of Tokyo Hospital. These included 54 cases of unilateral IMBT and 
17 cases of unilateral EMBT and four cases of bilateral EMBTs. Two of the 
IMBTs were in coexistence with mature cystic teratoma (MCT).  
The discrepancy between the number of IMBTs and EMBTs is due to the 
relative rarity of EMBTs. We included all EMBTs that were resected between 
1989 and 2011. Since IMBTs during this period far outnumbered EMBTs, we 
randomly selected 54 cases, which is a substantial number for comparative 
analysis. We also added 22 cases of SBT to the series. Hematoxylin and eosin 
(H&E)-stained slides of all cases were reviewed. Histological diagnosis was 
based on the most recent criteria of the WHO. 
 
Preparation of tissue samples and immunohistochemistry 
All tissue samples were fixed in formalin and embedded in paraffin. For 
immunohistochemistry, we arranged all MBTs (54 IMBTs and 25 EMBTs) and 
all 22 SBTs in tissue microarrays (TMAs) with duplicate 2-mm cores obtained 
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from each tumor. For those EMBT cases with bilateral involvement, tumors in 
the right and left ovaries were submitted separately. TMAs were cut into 4-μm 
thickness. 
To perform immunohistochemistry deparaffinization, antigen retrieval 
with Ventana CC1 buffer has done. Immunohistochemistry has carried out using 
the Benchmark XT Automated immunohistochemistry system (Ventana Medical 
Systems, Tucson, AZ, USA). Primary antibody staining and detection curried out 
using Ventana/EIEW DAB Universal Kit with validated reagents. After staining 
on the instrument, slides were dehydrated through graded alcohols to xylene and 
a coverslips were applied. 
For immunohistochemistry, MUC1 (clone:MA695), MUC2 (clone:Ccp58), 
MUC5AC (clone:CLH2), MUC6(clone:CLH5), Cytokeratin 20 (clone: Ks 20.8), 
and CA125 (clone: Ov 185:1) were obtained from Novocastra. CK7 (clone:OV-
TL12/30) and Vimentin (clone: V9) obtained from DakoCytomation. CLDN18 
(clone:poly) obtained from Zymed Laboratories. CDX2 (clone:CDX2-88) 
obtained from CellMarque, Estrogen receptor (clone:ER1D5) and Progesterone 
receptor (clone:A9621A) obtained from Ventana. Immunohistochemistry for 
CLDN18, MUC1, MUC2, MUC5AC, MUC6, CK7, CK20, CDX2, CA125, ER, 
PgR, and vimentin were performed in all ovarian borderline tumors. Antibodies 
used in this study are detailed in Table 1.  
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Interpretation of immunohistochemistry  
Immunoreactivity was interpreted based on the presence of cytoplasmic 
staining for CK7, CK20, and vimentin; nuclear staining for CDX2, ER, and PgR; 
membranous staining (with or without cytoplasmic staining) for CA125; and 
luminal/apical or combined luminal and cytoplasmic staining for MUCs. 
CLDN18 expression was evaluated based on the existence of basolateral 
membrane staining. Evaluation of immunohistochemistry was performed by two 
authors (SAH and DM), who specialize in gynecological pathology. 
Immunohistochemical reactions were scored based on the percentage of positive 
cells and graded as 0 (totally negative), 1+ (1%–4%), 2+ (5%–14%), 3+ (15%–
49%), and 4+ (≥50%). The average tumor cell positivity in two TMA cores was 
calculated. Each core was scored individually then the mean of the two readings 
was calculated. Appropriate positive and negative controls were included. 
 
Hierarchical clustering of ovarian borderline tumors according to their 
immunophenotype 
Unsupervised two-way hierarchical clustering was performed based on 
Euclid distances and average linkage clustering algorithms in sample directions 
and antibody directions using the Cluster software version 3.0 (Stanford 
University, http://bonsai.ims.u-
tokyo.ac.jp/~mdehoon/software/cluster/software.htm#ctv).  
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All IMBTs, EMBTs, and SBTs were included in the analysis. For the expression 
level of each protein, data on the percentage of positive cells detected by 
immunohistochemistry were used. A heat map was drawn using the Java 
TreeView software (Alok, http://jtreeview.sourceforge.net/). 
 
Statistical analysis 
Statistical analysis was performed using Fisher’s exact test. Statistical 
analyses were performed using the StatView software version 5.0 (SAS Institute, 
Cary, NC), and a value of P < 0.05 was considered to indicate statistical 
significance. 
 
 
Results 
Immunohistochemical comparison of IMBT and EMBT 
To reveal the characteristics of mucinous epithelium that comprise IMBT 
and EMBT, we initially analyzed the expression of markers that are known to 
represent either gastric or intestinal differentiation. The results are shown in 
Table 2. Positive immunoreactivity for CLDN18, a pan-gastric marker, was 
observed in nearly all cases (98%) of IMBTs, whereas EMBTs were usually 
CLDN18-negative (Figure 1). CLDN18 stained more than 50% of the tumor cells 
(4+) in the majority of IMBTs (48 of 56 cases). Diffuse basolateral staining was 
detected, especially in IMBTs that comprised stratified columnar mucinous 
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epithelium that resembled gastric foveolar-type epithelium. However, we also 
found CLDN18-positivity in the epithelium of IMBTs that contained scattered 
goblet cells (Figure 1). Almost all EMBTs were completely negative for 
CLDN18 with the exception of one case that revealed focal positivity.  
In addition to CLDN18 expression, significant differences between 
IMBTs and EMBTs were found with regard to the expression of MUCs and 
CDX2 (Figure 2). MUC5AC, a gastric foveolar epithelial marker, was more 
frequently expressed in IMBTs (93%) than in EMBTs (72%) (P = 0.0307). 
Further, most IMBTs showed 3+ and 4+ immunoreactivity for MUC5AC. In 
contrast, MUC5AC expression in EMBTs was usually focal (1+ and 2+) or 
negative. Markers of intestinal differentiation, such as MUC2 and CDX2, were 
expressed in less than half of IMBTs (33% and 48%, respectively). Expression of 
MUC2 and CDX2 in IMBT was usually focal and patchy (1+ and 2+), and 
diffuse (4+) immunoreactivity for these markers was found only in 3% and 5% of 
the cases. EMBTs were almost always negative for MUC2 and CDX2. MUC6, a 
marker for gastric pyloric gland-type epithelium, was negative in most IMBTs 
and EMBTs. MUC1 expression was seen more frequently in EMBTs (100%) 
compared with IMBTs (44%).  
Expression of conventional markers, including CK7, CK20, ER, PgR, CA-
125, and vimentin, was also evaluated in IMBTs and EMBTs. The results are 
shown in Table 3. In our series, all IMBTs and EMBTs expressed CK7. The 
remaining markers were differentially expressed in IMBTs and EMBTs (P < 
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0.0001). IMBTs are roughly characterized by a CK20+/ER-/vimentin- 
immunophenotype, whereas most EMBTs display a CK20-/ER+/vimentin+ 
pattern (Figure 3). CK20 expression was observed in 80% of the IMBTs. The 
extent of CK20-positivity was variable among the IMBT cases. EMBTs were 
almost always negative for CK20. Markers that were positive in all EMBTs 
included ER, vimentin, and CA125. The expression of ER, vimentin, and CA125 
in IMBTs was less frequent (4%, 2%, and 35%, respectively). Finally, PgR can 
be listed as another positive marker for EMBTs. However, the expression of PgR 
in EMBTs was slightly less frequent (80%) compared with that of ER, and ER 
staining tended to be more diffuse. 
 
Immunophenotype of SBTs and hierarchical clustering of ovarian 
borderline tumors 
We performed immunohistochemistry for all markers listed above in 22 
cases of SBT. The results are shown in Table 4. Our investigation revealed that 
all SBTs were negative for CLDN18. Markers commonly expressed in SBTs 
included MUC1, CK7, ER, CA125, and vimentin. The dendrogram depicted in 
Figure 4 is the result of hierarchical clustering of IMBTs, EMBTs, and SBTs 
according to their immunoprofile. This dendrogram shows the degree of 
relatedness between the protein expression patterns detected by the 12 antibodies 
across the 101 cases of ovarian borderline tumors, with short branches indicating 
a high degree of similarity in the staining pattern. In the dendrogram, IMBTs 
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comprised a distinct group that was separate from the EMBT/SBT group. Based 
on the analyses of these 12 markers, EMBTs and SBTs were not clearly 
separated. Rather, similarities in the immunophenotypes of EMBTs and SBTs 
were highlighted in the dendrogram. 
 
Discussion 
Evidence of altered claudin expression in various human neoplasms has 
been accumulating rapidly. Expression of CLDN18 has been studied in various 
types of human cancers and normal tissues (26-34). Two alternatively spliced 
variants are present in mice: Variant 1 (claudin18a1) is expressed in the lung, 
whereas variant 2 (claudin18a2) is expressed in the stomach (30, 32). In normal 
human tissues, expression of claudin18a2 is confined to gastric epithelial cells 
(foveolar, endocrine, parietal, and chief cells) and duodenal Paneth cells, and is 
not expressed in other organs, such as the esophagus, colon, pancreas, and lung 
(26, 30, 32, 35). CLDN18 is now considered to be a highly selective 
immunohistochemical marker of gastric lineage, and its expression is considered 
to determine the gastric phenotype in neoplastic conditions (27-29, 34). 
Sanada et al. (32) used immunohistochemistry to reveal that CLDN18 is 
highly expressed in normal gastric cells and that its expression is retained in 
approximately half of gastric cancers. Interestingly, they further showed that 
CLDN18 is downregulated in gastric epithelium with intestinal metaplasia and 
gastric cancers with an intestinal phenotype. Our group recently showed that a 
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subset of intrahepatic cholangiocarcinomas and pancreatic ductal carcinomas 
show a CLDN18-positive gastric phenotype (27, 28). It is of note that 
upregulation of CLDN18 occurs in the early stage of cholangiocellular and 
pancreatic carcinogenesis, as shown by CLDN18-positivity in precancerous 
lesions such as pancreatic intraepithelial neoplasias and biliary intraepithelial 
neoplasias. 
 
The current study is the first to investigate CLDN18 expression in ovarian 
borderline tumors. We demonstrated that the CLDN18-positive 
immunophenotype is specifically observed in IMBTs and not in EMBTs or SBTs. 
Another gastric marker, MUC5AC, which is expressed in normal gastric foveolar 
epithelium, was also frequently expressed in IMBTs, giving further support to the 
gastric differentiation of the IMBT epithelium. Since, previous reports have 
shown that normal endocervical glands frequently express MUC5AC (36, 37) we 
believe that focal positivity observed in EMBTs are most likely due to the 
MUC5AC antibody reacting to Müllerian-type mucinous epithelium that does not 
necessarily have gastric foveolar-type characteristics. In the past, the presence of 
goblet cells has been emphasized as a characteristic of IMBTs that can be 
observed in almost all cases (10, 12, 13) and a number of studies have focused on 
the expression of intestinal markers such as CDX2 and MUC2 as key 
immunophenotypes of IMBT (5, 15, 38). However, similar to some of the 
previous reports (38, 39) CDX2 and MUC2 expression in IMBTs was observed 
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in less than half of the cases, and their immunoreactivity was often focal in this 
study. Therefore, we conclude that in general, IMBTs are essentially composed 
of gastrointestinal-type mucinous epithelium, the predominant component of 
which is gastric-type rather than intestinal-type epithelium. This notion coincides 
with the morphological assessment of IMBTs by us and other researchers who 
consider that most mucinous epithelium in IMBTs resembles foveolar-type 
gastric epithelium (5, 17). Therefore, we propose abandoning the nomenclature 
“intestinal-type mucinous borderline tumor” and replacing it with 
“gastrointestinal-type mucinous borderline tumor” to avoid further confusion. 
Our immunohistochemical panel highlighted the differences between 
EMBTs and IMBTs. Similarities between EMBTs and SBTs have repeatedly 
been described from the morphological and immunohistochemical points of view 
(5, 6, 19). Recent studies have reported that EMBTs share features with low-
grade endometrioid tumors (borderline tumors and carcinomas), such as frequent 
association with endometriosis and frequent loss of ARID1A expression (11).  
Currently, it is not clear whether EMBTs are closer to SBTs or low-grade 
endometrioid tumors. We recognize EMBT as a distinct Müllerian-type tumor 
that shows a variable degree of mucin production. In fact, our study revealed 
Müllerian immunophenotypes of EMBTs, such as positivity for ER, PgR, CA-
125, and vimentin. Furthermore, hierarchical clustering of ovarian borderline 
tumors (IMBTs, EMBTs, and SBTs) according to their protein expression 
resulted in grouping EMBTs and SBTs together in a cluster that was completely 
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separate from the IMBT cluster. Although the number of antibodies applied in 
this study was limited and there was limitation in terms of assessing intratumoral 
heterogeneity due to the use of TMAs, the data clearly show that EMBT and 
IMBT are two distinct neoplasms and that the former is a part of the ovarian 
Müllerian-type tumor spectrum. 
From a diagnostic standpoint, pathologists may occasionally encounter 
ovarian mucinous tumors that are difficult to classify as either IMBT or EMBT. 
In such instances, the best immunohistochemical panel we propose is a 
combination of CLDN18, CK20, ER, and vimentin. IMBTs most frequently 
show a CLDN18+/CK20+/ER-/vimentin- pattern, whereas EMBTs are almost 
always CLDN18-/CK20-/ER+/vimentin+. 
In summary, we report overexpression of a gastric marker, CLDN18, in 
ovarian IMBTs. The distinct nature of IMBTs and EMBTs was elucidated 
through immunohistochemical analyses using a panel of antibodies including 
CLDN18. We also showed that CLDN18 can serve as a good diagnostic marker 
to distinguish IMBT from EMBT.  Taking these results into consideration, we 
hope to emphasize that IMBTs are essentially “gastrointestinal-type mucinous 
borderline tumors” and that EMBTs are “Müllerian-type mucinous borderline 
tumors.”  
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CLDN18 is specifically expressed in intestinal-type mucinous 
adenocarcinoma (IMCa) among ovarian cancers 
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Background 
Ovarian epithelial carcinoma is generally classified into five major 
categories: Mucinous adenocarcinoma (MCa), Endometrioid carcinoma (EMCa), 
Clear cell carcinoma (CCCa), High grade serous carcinoma (HGSCa) and Low 
grade serous carcinoma (LGSCa). Each of these subtypes is a distinct disease 
(40) . 
Mucinous adenocarcinoma is relatively uncommon. Unlike mucinous 
borderline tumors, they have not been clearly subclassified into intestinal and 
endocervical-types. However, histological features of most mucinous 
adenocarcinomas are of (gastro-) intestinal-type, and most gynecological 
pathologists regard them as intestinal-type mucinous adenocarcinoma (IMCa). In 
fact, many studies revealed that nearly all cases of IMCas have coexisting areas 
of IMBTs, which accounts for 5 to 70% of the whole tumor (41-43). IMCa is 
known for its poor prognosis and chemoresistance nature. About 80% of these 
tumors are confined to the ovary (stage I) at the time of diagnosis (41, 42). 
Tumors in advance stage have an extremely poor prognosis.  
The age of patients with IMCa ranges from 14-87 years with a mean of 39 
to 50 years (41-43) . Most IMCas are from 8 to 40cm (mean 16-19) in greatest 
dimension (41). IMCa is reported to be typically unilateral. Only about 5% or 
less is bilateral (41, 42). They are usually cystic, microcystic and most often they 
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appear multicystic (44). Solid areas and firm nodules are also common. In 4% of 
cases, the tumors are predominantly or entirely solid (44). IMCa usually shows 
two different patterns of stromal invasion: expansile and infiltrative. In expansile 
invasion the tumor glands are closely packed, in a back to back manner with little 
or no intervening ovarian stroma. This type of invasion is relatively common and 
usually difficult to distinguish from non-invasive carcinoma or from IMBTs. In 
contrast, infiltrative invasion is easily recognized by irregular glands, tubules, 
tumor nests, cords and cells that haphazardly infiltrate within reactive ovarian 
stroma (42). This type of invasion is usually called destructive stromal invasion 
(42). The existence of infiltrative invasion always raises concern for metastatic 
carcinoma from elsewhere in the body.  
For successful specific treatment, it is very important to correctly 
distinguish IMCas from other non-mucinous ovarian adenocarcinomas, because 
the treatment option and response to therapy is different in each subtype. 
Although identification of intracytoplasmic mucin is highly diagnostic in IMCa, 
many tumors lack obvious mucin in large parts of tumor, and their morphology 
simulate those of endometrioid or other subtypes of non-mucinous ovarian 
cancers. In such instances, distinction with other subtypes of non-mucinous 
ovarian adenocarcinoma is very difficult, and the tumor can easily be 
misdiagnosed as endometrioid or other type of non-mucinous ovarian cancer. 
Unfortunately, there are only few reliable immunohistochemical markers 
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available for distinction between IMCa and other subtypes of primary ovarian 
adenocarcinomas. 
Another important issue in the diagnosis of primary ovarian IMCa is their 
distinction from metastatic carcinomas involving the ovary. Since, the ovary is a 
common site for metastatic involvement, the possibility of metastatic carcinoma 
always needs to be considered when an ovarian mucinous tumor is examined. 
Always, a high index of suspicion is needed by pathologists as well as 
gynecologists to avoid misclassification of metastatic tumor as a primary ovarian 
adenocarcinoma. Metastatic tumors that usually resemble ovarian IMCa, are 
from the gastrointestinal-tract, especially from the lower gastrointestinal-tract 
(45), appendix (46, 47), pancreas (48), biliary-tract and stomach (49). 
Carcinomas from the lower gastrointestinal-tract (colorectum) are the most 
frequent tumors that metastasize to the ovaries. Low grade or benign looking 
areas are often found within the metastatic tumors, and they intensify diagnostic 
confusion. In some cases, the primary site tumor may not be apparent at the time 
of diagnosis, and metastatic ovarian tumor can be the first manifestation of 
undiagnosed non-ovarian primary (49-51). Clinical information such as 
preoperative evaluation of tumor markers, tumor size information, and whether 
the ovarian tumor is unilateral or bilateral are reported to be helpful in 
distinguishing primary ovarian and metastatic adenocarcinoma. Microscopical 
findings and immunohistochemistry may also be useful. However, due to 
overlapping of the features, diagnostic uncertainty usually remains high. 
28 
 
In general, histological features are helpful to differentiate primary from 
metastatic mucinous tumors. Primary IMCa is more likely to have an expansile 
pattern of invasion, complex papillary pattern, microscopic cysts, and necrotic 
luminal debris (52). The presence of a coexisting ovarian lesion (MA and or 
IMBT) can be supportive for diagnosis of a primary ovarian tumor, although it 
should be noted that these benign looking components may also exist even in 
tumors metastatic to the ovary from elsewhere. Diagnostic criteria which support 
metastatic nature include nodular growth pattern, ovarian surface involvement, 
infiltrative pattern of invasion, infiltrative single cell pattern, hilar involvement, 
and signet ring cells (9, 49).  
Recently Seidman et al (50) proposed an algorithm using two factors 
include tumor size and tumor laterality. Based on the proposed algorithm 
unilateral tumors with size being or greater than 10 cm are primary, while 
bilateral tumors, and unilateral tumors with size less than 10cm are all metastatic. 
According to the proposal, this algorithm will accurately classify tumors in over 
90% of the cases. In another study, performed by Khunamornpong et al, in a 
retrospective sample of patients with unilateral tumors greater than 10 cm, the 
tumor was diagnosed as a primary ovarian tumor in 50% of the cases with 10-
15cm, and 69% of those were greater than 15cm (51).  
Immunohistochemistry shall play an important role in distinguishing the 
primary ovarian from metastatic tumors. Cytokeratin (CK) and CDX2 staining 
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have been frequently used for this purpose (39, 53). A CK7 positive/CK20 
negative immunophenotypes is known to suggest a primary ovarian lesion, while 
CK7 negative/CK20 positive immunophenotype supports metastatic involvement 
(39, 53). However, mucinous tumors of the appendix or upper gastrointestinal 
tract origin stain with CK7 occasionally. Results of various previous studies 
suggest that we cannot rely on the CK7/CK20 immunoprofile alone.  
None of the above diagnostic tools are decisive alone. Uncertainty is 
always remaining high. Supportive and additional examination including 
immunohistochemistry is usually needed. 
 
 
Study aims 
In this study, we investigated the significance of CLDN18 expression in 
IMCas and variety of non-mucinous ovarian adenocarcinomas, as well as 
metastatic CRCs involving the ovary. Since intestinal-type mucinous 
adenocarcinoma was suspected to have gastric phenotype from morphological 
evaluation, we tried to confirm that by applying CLDN18 immunohistochemistry. 
We then, assessed the utility of CLDN18 immunohistochemistry in 
differentiating intestinal-type mucinous adenocarcinoma and other subtypes of 
non-mucinous ovarian adenocarcinomas, as well as metastatic colorectal 
carcinomas (CRCs) involving the ovaries. We also examined the expression of 
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other conventional markers (CK7, CK20, CDX2, MUC2, MUC5AC, and ER) in 
order to establish a panel of markers that can be useful for differentiating IMCas 
and metastatic CRCs involving the ovary. The usefulness of proposed algorithm 
that relies on size and laterality is also evaluated in this study.  
 
Materials and method 
Cases of mucinous adenocarcinomas including primary IMCas and 
metastatic CRCs involving the ovaries were included in this study. Tumor 
samples were collected from 35 patients. These included 19 primary IMCas and 
16 metastatic CRCs involving the ovaries. Fifteen of the IMCas were retrieved 
from the archives of the Department of Pathology at the University of Tokyo 
Hospital. Four of the IMCas were collected from the Department of Pathology at 
University of Teikyo Hospital. The histological slides of each case were 
reviewed, and the diagnosis was made according to the most recent WHO 
classification. Distinction between primary and metastatic tumor was based on 
the morphological and clinical presentation and in some cases with an aid of 
immunohistochemistry. Tumors were diagnosed as primary IMCa when they 
exhibited typical morphological features as described for primary IMCa (49, 51, 
52). Clinicopathological data of all patients were reviewed. The data regarding 
patients age, tumor size (maximal dimension), and laterality of all cases (primary 
and metastatic) were collected.  
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Following histological features were evaluated for all tumors: tumor 
growth pattern, types of invasion, surface involvement, and co-existing ovarian 
lesions. 
To evaluate the usefulness of proposed algorithm (50) in our cases, the 
primary and metastatic mucinous adenocarcinomas were compared by two 
factors including tumor laterality (unilateral versus bilateral) and tumor size 
(10cm or over versus less than 10 cm). 
 
Non-mucinous variants of primary ovarian adenocarcinoma 
Various subtypes of ovarian non-mucinous adenocarcinomas (n=202), 
were collected from the archives of the Department of Pathology, The University 
of Tokyo Hospital. These included 95 cases of clear cell adenocarcinoma (CCCa), 
38 cases of endometrioid adenocarcinoma (EMCa), 58 cases of high grad serous 
adenocarcinoma (HGSCa) and 11 cases of low grade serous adenocarcinoma 
(LGSCa). 
 
Preparation of the sample and Immunohistochemistry 
All tissue samples were ﬁxed in formalin and embedded in parafﬁn. For 
immunohistochemistry, we arranged CCCa (n=95), EMCa (n=38), HGSCa 
(n=58), LGSCa (n=11) and IMCa (n=12) in tissue microarrays (TMAs). The 
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TMAs were constructed from formalin fixed paraffin embedded tissues. 
Immunohistochemical comparison between primary IMCas and other non-
mucinous primary ovarian adenocarcinomas were performed using the sets of 
tumors included in these TMAs.  
In order to perform comparison between primary IMCas and metastatic 
CRCs involving the ovaries, we used a representative whole tissue section, so 
that the distribution of the positive cells can be thoroughly evaluated. Additional 
cases of IMCas were evaluated in whole section. Both primary IMCas (n=19), 
metastatic CRCs involving the ovary (n=16) were stained for comparison. 
To perform immunohistochemistry, deparaffinization and antigen retrieval 
with Ventana CC1 buffer was done. Immunohistochemistry was carried out using 
the Benchmark XT Automated immunohistochemistry system (Ventana Medical 
Systems, Tucson, AZ, USA). Primary antibody staining and detection were 
carried out using Ventana/EIEW DAB Universal Kit with validated reagents. 
After staining on the instrument, slides were dehydrated through graded alcohols 
to xylene and a coverslips were applied.  
Immunohistochemistry for CLDN18 was performed in all cases of IMCas, 
non-mucinous variants of ovarian adenocarcinomas and all metastatic CRCs 
involving the ovary. To compare the immunophenotype of IMCas and metastatic 
CRCs involving the ovary, additional markers such as MUCs (MUC2 and 
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MUC5AC), cytokeratins (CK7 and CK20), CDX2 and ER were also stained. 
Appropriate positive and negative control was used for all antibodies.  
 
Interpretation of immunohistochemistry 
Immunoreactivity was interpreted based on the presence of cytoplasmic 
staining for CK7, CK20, nuclear staining for CDX2 and ER, luminal/apical or 
combined luminal and cytoplasmic staining for MUCs. CLDN18 expression was 
evaluated based on the existence of basolateral membrane staining. Evaluation of 
immunohistochemistry was performed by two authors (SAH and DM), who 
specialize in gynecological pathology. Immunohistochemical reactions were 
scored based on the percentage of positive cells and graded as 0 (totally negative), 
1+ (1%–4%), 2+ (5%–14%), 3+ (15%–49%), and 4+ (≥50%). For TMA sections, 
the average tumor cell positivity in two cores was calculated. Each core was 
scored individually, and then the mean of the two readings was calculated. 
 
Statistical analysis 
Statistical analysis was performed using χ2 test for comparison between 
IMCas and non-mucinous subtypes of ovarian adenocarcinomas, and Fisher’s 
exact test for comparison between IMCas and metastatic CRCs involving the 
ovary. Statistical analyses were performed using the StatView software version 
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5.0 (SAS Institute, Cary, NC), and a value of P < 0.05 was considered to indicate 
statistical significance. 
 
Results  
In this study, none of the patients with primary IMCas had any history of 
previously diagnosed adenocarcinoma in other organs. In one patient, a 
synchronous advanced adenocarcinoma existed in the ascending colon. In this 
specific patient, the tumors in the ovary and ascending colon were resected 
simultaneously.  
The patients’ age with primary IMCas varied from 24–72. In 2 (10%) 
patients, the tumor involved bilateral ovaries. In 17 (90%) patients, the tumors 
were unilateral, and left ovarian involvement was relatively more frequent. 
Tumors sizes varied from 7cm to 30 cm. In 17 (90%) patients, the tumors were 
more than 10cm in greatest dimension. In 2 patients (10%), the tumors were less 
than 10cm. Histologically, the majority of tumors in this study showed expansile 
pattern of invasion. Only 3 cases, showed destructive or infiltrative stromal 
invasion. One of the tumors had a mature cystic teratoma in the background.  
All metastatic ovarian tumors in this study had typical morphological 
features of metastatic CRCs involving the ovaries (52). Tumors in this study 
originated from different primary sites including cecum (n=2), ascending colon 
(n=4), transverse colon (n=2), sigmoid colon (n=5), and rectum (n=3). Nodularity, 
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surface involvement, and stromal reaction were present in almost all cases. The 
patients’ age varied from 28 to 74. Bilateral ovarian involvement was found in 7 
(44%) patients. In 9 (56%) patients the tumors were unilateral and right and left 
ovaries were equally involved. The tumors were more than 10cm in 11 (69%) 
patients, while less than 10cm in 4 (25%). In one patient, the size information 
was not available. Among metastatic bilateral tumors, 4 of them were less than 
10cm, while 3 of them were greater than 10cm. Unilateral metastatic tumors 
(n=8) were all greater than 10cm in size. There is no unilateral metastatic tumor 
with size less than 10cm in this study. The summery of tumor size and laterality 
in both primary IMCas and metastatic CRCs involving the ovary is shown in 
Table 5. In 11 patients, both tumors (primary and metastatic) were resected 
simultaneously. In the remaining cases primary and metastatic tumors were 
resected separately. The time interval between metastatic tumor detection and 
primary tumor surgery varied from 1 to 3 years.  
 
Results of immunohistochemistry:  
CLDN18 is specifically expressed in IMCa among ovarian cancers  
The results of immunohistochemistry (TMA analysis) are summarized in Table 6. 
 CLDN18 expression was analyzed among verity of primary ovarian 
adenocarcinomas. Our immunohistochemical analyses revealed that CLDN18 is 
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exclusively expressed in IMCas. Diffuse membranous staining was found in 
nearly all cases of IMCas (11/12). There was only one case that was 
exceptionally CLDN18-negative. In that patient, coexistence of mature cystic 
teratoma was observed in the same ovary. In contrast to IMCas, nearly all other 
subtypes of non-mucinous ovarian adenocarcinomas (CCCa, EMCa, HGSCa, and 
LGSCa) were CLDN18-negative. Focal expression was found in three cases 
(6%) of endometrioid adenocarcinoma due to mucinous metaplasia which is 
commonly found in EMCas. The representative histology and CLDN18 
expression of each subtype is shown in Figure 5.  
 
Differential expression of CLDN18 and MUC5AC among IMCas and 
metastatic CRCs involving the ovary: 
In this study we also focused on the immunohistochemical comparison 
between IMCas and metastatic CRCs, since CRCs are the most frequent origin of 
metastatic ovarian cancers which cause diagnostic confusion. The results of 
immunohistochemistry are summarized in Table 7.  
As a result, positive immunoreactivity for CLDN18 was observed in 
majority (85%) of IMCas, whereas metastatic CRCs involving the ovary were 
usually CLDN18-negative (Figure 6). CLDN18 positivity was observed in more 
than 50% of the tumor cells (4+) in nearly half of the IMCas. In 3 cases, 
CLDN18 was exceptionally negative. Those cases included one that had mature 
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cystic teratoma in the background. In that case the coexisting low grade (IMBT 
and MA) components were also CLDN18-negative. Almost all metastatic CRCs 
involving the ovary were completely negative for CLDN18 (Figure 6) with the 
exception of two cases that revealed very focal positivity.  
In addition to CLDN18 expression, significant differences between 
primary IMCas and metastatic CRCs were found with regard to the expression of 
MUC5AC and CK7 (Figure 7). MUC5AC, was more frequently expressed in 
IMCas (84%) than in metastatic CRCs (19%) (P=0.0001). MUC5AC expression 
in IMCas was usually moderate-to-diffuse (2+, 3+ and 4+). In contrast, only three 
cases of metastatic CRCs expressed very focal (1+) MUC5AC positivity. CK7 
was exclusively expressed in IMCas (100%), whereas it was usually negative in 
metastatic CRCs involving the ovaries (P<0.0001). MUC2 was more frequently 
expressed in metastatic CRCs (87%) than in primary IMCas (37%) (P=0.0022). 
CK20 and CDX2 were almost always expressed by metastatic CRCs involving 
the ovaries (100%), whereas their positivity was slightly lower in primary IMCas 
(74%). CK20 and CDX2 expression was usually diffuse in metastatic CRCs 
involving the ovary, while it was usually focal and patchy in primary IMCas 
(Figure 8).  
In summary, IMCas usually demonstrate CK7+/MUC5AC+/CLDN18+ 
immunophenotype. Metastatic CRCs in the ovaries are usually CK7-
/CK20+/CDX2+/MUC5AC-/CLDN18-. 
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Discussion 
The expression pattern of various CLDNs in normal tissues, benign and 
malignant tumors is complex and mostly appears organ dependent (31). The 
abnormal expressions of various CLDNs have recently fascinated researchers 
(54). In general, the association between expression pattern of CLDNs and 
cancer is not fully studied. However, recently studies on cancer showed that the 
over or underexpression of at least one of the CLDNs is seen in various types of 
human cancers, suggesting that they probably have a role in cancer initiation or 
cancer progression. For example, underexpression of CLDN1 and CLDN7 occur 
in breast, colon, and head and neck cancer, whereas overexpression of CLDN3, 
and CLDN4 occur in ovarian, prostate, uterine and breast cancers (55-59). Some 
authors also reported the overexpression of CLDN18 in intrahepatic 
cholangiocarcinomas and pancreatic ductal carcinomas (27, 28).  
In the previous chapter, we have shown CLDN18 overexpression in 
intestinal-type mucinous borderline tumor. This has led to the assumption that 
CLDN18 overexpression occurs in IMCas, too.  
This is the first study to evaluate CLDN18 in ovarian IMCas. Our results 
showed that CLDN18 is overexpressed in nearly all cases of IMCas with diffuse 
pattern of expression. Interestingly, all other non-mucinous variants of ovarian 
adenocarcinomas were negative, except for few exceptional EMCas. Since, 
CLDN18 expression represents gastric phenotype in neoplastic conditions (26-29, 
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34), its expression in ovarian IMCas suggests that they have a gastric phenotype 
as well. Combined with the data in the previous chapter, we now conclude that 
IMBTs and IMCas are the same lineage of tumor characterized by CLDN18-
positive, gastric phenotype. At this point, it is not clear whether CLDN18 
expression has any prognostic value or not. To clarify this issue, further 
investigation in a larger case series is needed. 
Irrespective of their role or contribution in cancer progression the CLDNs 
recently hold a great hope as a target for the future therapeutic intervention. Their 
unusual expression pattern in various types of human cancers suggests the utility 
for detection, diagnosis and treatment of drug resistant human cancer (58, 65-67). 
IMCa is known for its chemoresistant nature to conventional therapeutic agent. 
CLDN18 overexpression in ovarian IMCa, as shown in this study suggests that it 
may be a potential target for future cancer therapy.  
The differential expression pattern of CLDN18 in IMCas and other 
subtypes of non-mucinous ovarian carcinomas has a significant diagnostic value. 
To date there is no specific marker available distinguishing IMCa from other 
subtypes of ovarian non-mucinous adenocarcinomas, especially endometrioid 
carcinoma, CCCa and HGSCa. Therefore, in problematic cases when histological 
distinction is difficult, CLDN18 can serve as a useful marker for differential 
diagnosis.  
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One of the biggest challenges in diagnosis of ovarian mucinous tumor is 
its distinction from metastatic tumors. In fact, the ovary is a common site for 
metastatic involvement. Tumors of the gastrointestinal-tract, breast and uterine 
cervix often metastasize to the ovaries. In every patient with mucinous 
adenocarcinoma, it is necessary to rule out the possibility of metastatic 
involvement. Among all tumors, those with colorectal origin most frequently 
metastasize to the ovaries and cause diagnostic confusion. During the last 
decades, there has been a dramatic change in diagnostic criteria for 
differentiation between primary ovarian and metastasis from elsewhere (42, 49). 
According to the recently published reports, the frequency of primary mucinous 
adenocarcinoma in the ovary is much less common compared to what have been 
previously reported (15, 50). Metastatic mucinous adenocarcinomas were 
reported to be much more frequent than primary mucinous adenocarcinoma. 
Some reports described that most of the cases that were previously diagnosed as 
primary, were actually metastatic from non-ovarian primaries. A ratio of 
metastatic to primary tumor, which is 3.2:1, has previously reported (50). 
Histological feature and immunohistochemistry is useful for differentiation. 
However, many features may be overlapping between primary and metastatic 
tumors.  
According to the proposed algorithm (50), if ovarian mucinous tumor is 
unilateral, and over 10cm in size, it is most likely primary IMCa. Bilateral tumors 
and unilateral tumors with size less than 10cm are metastatic. This algorithm is 
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useful for tumor classification. But, according to our observation, there was some 
difference in the distribution of metastatic mucinous adenocarcinoma in our 
study compared to what have been previously proposed. In our study, we focused 
only on metastatic ovarian lesions from colorectal primaries. Most of the 
metastatic CRCs are tended to be larger than those reported by Seidman et al. In 
general, our data showed that primary IMCa with bilateral ovarian involvement 
and metastatic CRCs with size over than 10cm is not uncommon. 90% of IMCas 
in this study were unilateral, while the remaining 10% displayed bilateral ovarian 
involvement. In 90% of IMCas, the tumors were over than 10cm in greatest 
dimension, which is consistent with Sideman’s algorithm. However, we have got 
different data with regards to metastatic tumors. In our study, 56% of metastatic 
tumors were unilateral, while 44% were bilateral. Most of the metastatic tumors 
in our study were larger than 10 cm. 69% of metastatic tumors in our study was 
more than 10cm in greatest dimension. In addition the frequency of bilaterality 
was lower (7/16, 44%), compared to 94% reported by Seidman et al.  
According to our results the algorithm of size and laterality cannot be 
highly predictive and reliable for classifying tumor as primary or metastatic. 
Therefore, in addition to clinical and histological information other auxiliary 
methods for differential diagnosis always should consider, especially 
immunohistochemistry. 
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Immunohistochemistry is also widely used for distinction between 
primary and metastatic tumor, although the number of immunohistochemical 
markers available right now is not sufficient. In recent years, 
immunohistochemistry, especially differential expression of cytokeratins (CK7, 
CK20) and CDX2 staining, has been widely used as an aid for distinction 
between primary IMCas and metastatic CRCs involving the ovary. Since, CK7 is 
usually expressed in primary ovarian IMCas while, metastatic CRCs usually 
express CK20 and CDX2 (39, 53).  
Our immunohistochemical comparison revealed that “CLDN18” is a novel 
marker which is useful for distinguishing, primary IMCas from metastatic CRCs 
involving the ovary. Our study demonstrated diffuse CLDN18 expression in 85% 
of ovarian IMCas with the exception of three cases, including the one that arose 
in association with mature cystic teratoma. In contrast, metastatic CRCs were 
nearly always CLDN18-negative with exception of two cases, which revealed 
very focal positivity. MUC5AC is another marker that differentially expressed in 
primary IMCas and metastatic CRCs. Therefore, it can be another useful marker 
for differential diagnosis between these two lesions.  
Expression of CK20 was found in all cases of metastatic CRCs. However, 
CK20 expression was variable in primary IMCas. They were frequently positive 
in IMCas, but not in a diffuse manner. In contrast, most cases of metastatic CRCs 
were diffusely positive for CK20. Looking at the results, we believe that a panel 
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including (CLDN18, CK7, CK20, MUC5AC, and CDX2) is the best combination 
of markers for differential diagnosis between primary IMCas and metastatic 
CRCs involving the ovary. It is also important to know that CLDN18 usefulness 
is limited to IMCa vs. metastatic CRCs in the ovary, since it can’t be used for 
distinction between IMCa and metastatic pancreatic and gastric carcinomas 
which are reported to be CLDN18-positive formerly (26-28, 32). 
The results of our study and previous reports showed a significant role for 
CLDNs expression in various types of human neoplasms. Its clinical application 
can be significant in terms of tumor detection, tumor diagnosis and tumor 
treatment. According to our findings, CLDN18 immunohistochemistry has a 
significant role in diagnosis of intestinal-type ovarian mucinous tumors. We can 
easily distinguish intestinal-type and endocervical subtypes of ovarian mucinous 
tumors by using CLDN18 immunohistochemistry. In terms of distinction 
between mucinous and non-mucinous subtypes of ovarian tumors, and distinction 
between primary IMCas and metastatic CRCs involving the ovary, CLDN18 
immmunohistochemistry plays a significant role. All these finding suggest a 
significance clinical role for Claudin18 immunohistochemistry which is 
important for the patients’ management.  
Additionally, since a large numbers of human cancers overexpress various 
CLDN family members, along with the cell-surface localization of CLDNs, it 
makes these proteins (CLDNs) attractive molecular targets for cancer treatment. 
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However, the clinical application of CLDNs-targeted therapy may face several 
obstacles. The agents designed to disrupt tight junctions, such as CPE 
(clostridium perfringens enterotoxin) increases tight-junction’s permeability 
which may be beneficial in providing enhanced uptake of chemotherapeutic 
agents. Since, CPE has been the most frequently studied CLDN-targeted 
therapeutic and its ability to rapidly lyse tumour cells of several cancer types has 
been demonstrated. Therefore, CPE might be best suited to local administration 
such as in the intraductal treatment of breast carcinoma in situ (88) or 
intraperitoneal treatment of ovarian cancer (89). 
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Majority of mucinous cystadenomas (MAs) are of 
gastrointestinal-type and their small subset originate 
from Müllerian-type epithelium 
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Background 
Mucinous cystadenoma (MA) is the most common mucinous tumor in the 
ovary. They are always benign and comprise 80% of all ovarian mucinous 
tumors (4, 40). These tumors are usually large, and unilateral in about 95% of 
cases. About 5% of these tumors are bilateral (4, 40). They have a smooth 
external surface and typically composed of multiple smooth walled cystic lesions 
with various sizes.  Histologically, a non-stratified mucinous epithelium 
resembling gastric foveolar-type epithelium is usually observed in mucinous 
cystadenoma (40). Intestinal-type mucinous epithelium including various 
numbers of goblet cells is also occasionally observed. The epithelium in MA is 
tall columnar with intracellular mucin having a small basal nuclei (40). 
Stratification and tufting are generally absent. MA generally lacks atypia or they 
may have a very mild or focal atypia (4). Rarely these tumors appear multilocular 
cystic with papillary architecture.  
The immunophenotype of these tumors are not fully understood, and not 
much has been described in the literature. These tumors are usually diagnosed 
simply as “mucinous cystadenoma” without subclassification such as intestinal-
type or endocervical-type as we do in mucinous borderline tumors. 
They are parts of ovarian epithelial neoplasm and currently accepted as a 
precursor for IMBTs and IMCas. It is generally believed that stepwise malignant 
transformation occurs from MAs to IMBTs and to IMCas. According to some of 
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the previous studies nearly all cases of IMCas have areas of MA as well as IMBT 
(41-43). Thus, it can be speculated that most MAs are of gastrointestinal-type 
lineage. 
The histogenesis of these tumors is not clearly understood. There are 
several hypotheses regarding the histogenesis of these tumors. Some 
investigators believe that most of these tumors are derived from ovarian surface 
epithelium that undergoes a metaplastic process (68-71). At the same time, a 
teratomatous origin is suggested. Mucinous tumors are present in 11% of ovarian 
mature cystic teratomas (MCT), and conversely around 5% of ovarian mucinous 
tumors contain a teratoma (68, 72-75). Since, mature cystic teratomas (MCT) 
have gastrointestinal-type mucinous epithelium, it is certainly possible that 
mucinous tumors associated with MCTs arise from those gastrointestinal 
elements in MCT and have a germ cell or teratomatous origin, rather than ovarian 
surface epithelium (75).  
The association of mucinous tumor with Brenner tumor (BT) is also 
reported in the past. Metaplastic mucinous epithelium is occasionally observed in 
the center of transitional cell nests of the Brenner tumor (BT). It is generally 
believed that those mucinous tumors associated with BT arise from areas of 
metaplastic mucinous epithelium existing in the BT nests (73, 75, 76). Molecular 
change including activating KRAS mutation is also reported more frequently in 
mucinous ovarian tumors. The frequency is higher compare to other histological 
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subtypes. According to the previous studies, mutation of KRAS is more common 
in endocervical-type mucinous tumors than those of gastrointestinal-type (85-87). 
The association between gastrointestinal-type mucinous epithelium of the 
mucinous cystadenomas and Müllerian-type epithelium such as those of 
endometrial cyst (EC), and other ER-positive epithelium has not been clearly 
illustrated in the past. According to our observation, mucinous cystadenoma is 
occasionally associated with Müllerian-type lesions such as endometrial cyst 
(EC). However, still it is largely unknown whether Müllerian-type epithelium or 
epithelium of Müllerian duct derivative has a potential to bear gastrointestinal-
type mucinous epithelium or not.  
 
Study aims:  
In this study, we attempted to elucidate the direction of differentiation of 
mucinous epithelium that constitutes mucinous cystadenomas. Special attention 
was paid to the existence of gastrointestinal-type mucinous epithelium, and its 
association with Müllerian-type epithelium.  
To determine the histogenesis of gastrointestinal-type mucinous 
epithelium, we have also attempted to clarify the distribution of CLDN18-
positive gastric-type mucinous epithelium in variety of ovarian lesions, including 
benign teratomatous and metaplastic mucinous epithelium, and non-neoplastic 
Müllerian duct derivatives. 
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Materials and methods  
Tissue sample 
In this study, the following tissue samples were immunohistochemically 
analyzed: Mucinous cystadenomas, mucinous epithelium in mature cystic 
teratomas, metaplastic mucinous epithelium in ovarian lesions such as Brenner 
tumor and endometrial cyst, non-mucinous ovarian lesions and non-neoplastic 
Müllerian duct derivatives.  
Ovarian Mucinous Cystadenoma 
A large series of MAs including unilateral tumors from 139 patients were 
retrieved from archives of Department of Pathology at The University of Tokyo 
Hospital. In all of these cases, the histological slides have been reviewed, and 
tumor diagnosis was made according to the most recent WHO classification. The 
histological features of all tumors including types of epithelium lining the cystic 
cavities, and tumor growth pattern were evaluated. Coexistence of other lesions 
in the ovary especially, endometriosis, endometrial cyst, mature cystic teratoma, 
and Brenner tumor were also recorded.  
Teratomatous and metaplastic mucinous epithelium in the ovary  
Gastric and intestinal-type mucinous epithelium in MCT, and variety of 
metaplastic mucinous epithelium in the ovary were also analyzed in this study. 
We analyzed 13 cases of MCTs that contained gastric-type and/or colonic-type 
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mucinous epithelium, five endometrial cysts (ECs) with focal mucinous 
metaplasia, and three cases of Brenner tumors (BTs) with focal mucinous 
metaplasia.  
 
Benign non-mucinous ovarian lesions and non-neoplastic Müllerian duct 
derivatives. 
Benign non-mucinous ovarian lesions, including eight serous 
cystadenomas (SCAs), 10 endometrial cysts (ECs) without mucinous metaplasia, 
and five surface epithelial inclusions, were added to the series. Further, the 
following cases of non-neoplastic Müllerian duct derivatives were also included 
in this study:  Fallopian tube epithelium of six patients, endometrial epithelium of 
41 patients (11 in the proliferative phase, 12 in the secretory phase, six in the 
menstrual phase, and 12 in the gestational phase), endocervical epithelium of six 
patients, and endometriosis of six patients. 
 
Preparation of tissue sample and immunohistochemistry 
All tissue samples were ﬁxed in formalin and embedded in parafﬁn. The 
tumors were initially evaluated, on morphological basis, for the presence or 
absence of gastrointestinal-type mucinous epithelium, and Müllerian-type 
epithelium. As previously described, gastrointestinal-type mucinous epithelium is 
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tall columnar in appearance, and the cells have small basal nuclei and 
intracytoplasmic mucin. They look similar to gastric foveolar and pyloric-type 
epithelium, or epithelium of intestine which have goblet cells. Müllerian-like 
epithelium is also tall columnar or cuboidal in appearance, show ciliation and 
focal papillary change on the surface with no goblet cells. Morphologically they 
are similar to the uterine cervical glandular epithelium or epithelium of EMBT 
and SBTs.  
A representative slide was chosen for morphologically purely 
gastrointestinal-like MAs and purely Müllerian-like MAs. For those cases in 
which transition from Müllerian-like epithelium to gastrointestinal-like 
epithelium was observed, or suspected, slides that contained such areas were 
selected for immunohistochemistry. 
A representative whole tissue section was also selected for the remaining 
benign teratomatous mucinous lesions, metaplastic mucinous lesions, non-
mucinous and non-neoplastic Müllerian duct derivatives. We arranged benign 
endometrial epithelium in another TMA with a single 2-mm core obtained from 
each case. Both whole sections slides and TMAs were cut into 4μm thickness for 
immunohistochemical analysis. Immunohistochemistry was performed in a 
method which is previously described (refer to page 16). 
To clarify the characteristics of mucinous epithelium in Mas, we 
performed immunohistochemistry. Although they usually consisted of gastric 
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foveolar-type epithelium, in some cases the characteristics of epithelium was 
vague and difficult to specify by histological examination only. For conclusive 
evaluation of the epithelial differentiation, we performed immunohistochemistry 
for CLDN18 (as a gastric marker), CDX2 (as an intestinal marker) and ER (as a 
Müllerian marker) in all cases of MAs. To detect CLDN18-positive gastric-type 
mucinous epithelium in benign ovarian lesions and Müllerian duct derivatives, all 
teratomatous mucinous lesions, metaplastic mucinous lesions, non-mucinous 
ovarian lesions and non-neoplastic Müllerian duct derivatives were stained with 
CLDN18 only.  
Interpretation of immunohistochemistry 
Immunoreactivity was interpreted based on the presence of nuclear stating 
for, ER and CDX2. CLDN18 expression was evaluated based on the existence of 
basolateral membrane staining. Immunohistochemical reactions were scored 
based on the percentage of positive cells and graded as 0 (totally negative), 1+ 
(1%–4%), 2+ (5%–14%), 3+ (15%–49%), and 4+ (≥50%).  
Finally, we defined the epithelium showing CLDN18+/CDX2±/ER- 
immunophenotype as pure gastrointestinal-type epithelium, and the epithelium 
showing CLDN18-/CDX2-/ER+ immunophenotype, designated as pure 
Müllerian-type epithelium. The epithelium showing CLDN18+/CDX2±/ER+ 
immunophenotype, designated as “mixed gastrointestinal/Müllerian-type 
epithelium”. 
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Statistical analysis 
Statistical analysis was performed using Fisher’s exact test. Statistical 
analyses were performed using the StatView software version 5.0 (SAS Institute, 
Cary, NC), and a value of P < 0.05 was considered to indicate statistical 
significance. 
 
Results:  
Morphologically, 14 cases of MAs coexisted with mature cystic teratoma 
(MCT), 6 cases were in transition or in coexistence with endometrial cyst (EC), 2 
cases coexisted with endometriosis and one case coexisted with Brenner tumor. 
In majority of mucinous cystadenomas the lining epithelium consists of 
gastric foveolar-type mucinous epithelium with flat apex that show no to mild 
stratification. The nuclei are uniformly located at the base of the cells. In addition, 
over 30 cases of MAs demonstrated varying numbers of goblet cells, suggesting 
their intestinal-type differentiation. 
In a small number of cases, the lining epithelium represented non–
gastrointestinal. The existence of ciliated change on the surface with focal 
papillary formation, and nuclear feature different from gastrointestinal-type 
epithelium were detected in these cases. Unlike, gastrointestinal-like MAs their 
nuclei were located in the mid part of cytoplasm, and had round shaped. These 
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features suggest Müllerian-type differentiation. There were also some cases 
which showed histological transition from morphologically Müllerian-type 
epithelium to morphologically gastrointestinal-type mucinous epithelium. In 
these cases, gastrointestinal-type mucinous epithelium usually predominated. In 7 
cases of mucinous cystadenomas, the cyst wall showed endometrial cyst-like 
changes such as fibrosis, hyalinization and hemosiderin deposition. 
 
Results of immunohistochemistry 
Mucinous cystadenomas  
The results of immunohistochemistry in mucinous cystadenomas are summarized 
in Table 8 and 9.  
Our immunohistochemistry results, revealed gastrointestinal phenotype as 
defined by CLDN18 and/or CDX2 positivity in vast majority of mucinous 
cystadenomas (93%, 129/139). CLDN18 was positive in 91% (127/139) of the 
cases, and almost all the cases showed diffuse expression pattern, since more 
than 50% of tumor cells were CLDN18 positive. CDX2 (intestinal marker) was 
expressed in 40/139 (29%) of MAs. The expression was focal with exception of 
three cases, which revealed diffuse positivity (Figure 9 and Figure 10). Based on 
these results, 71% (99/139) of mucinous cystadenoma in our study can be 
55 
 
categorized as a purely gastrointestinal-type MAs, which characterized by 
(CLDN18+/CDX2±/ER-) immunophenotype (Figure 9 (A-D) and Figure 10). 
In 12 cases of MAs, we found purely gastrointestinal-type mucinous 
epithelium (CLDN18+/CDX2±/ER-) in transition from Müllerian-type 
(CLDN18-/CDX2-/ER+) epithelium (Figure 11). In most of these cases, 
predominant component was gastrointestinal-type. In 18 cases of MAs, the 
tumors contained mixed gastrointestinal and Müllerian-type epithelium 
characterized by CLDN18+/CDX2±/ER+ immunophenotype. The positivity of 
ER in these cases varied from weak or focal to diffuse and strong. We regard this 
finding as evidence, which suggest transformation of Müllerian-type epithelium 
to gastrointestinal-type epithelium. The representative areas are shown in Figure 
12. 
In 8 (6%) cases, the tumors showed only ER positivity, and we regarded 
as “pure Müllerian-type”. In these cases immunoreactivity for other markers 
(CLDN18 and CDX2) was completely negative. This immunophenotype is 
purely Müllerian (CLDN18-/CDX2-/ER+). The representative histology of 
purely Müllerian-type MAs along with their ER, CLDN18 and CDX2 expression 
is shown in Figure 13. Around 1% of mucinous cystadenoma in this study 
represented non-specific histological and immunohistochemical feature. All three 
markers were negative in these cases. They were considered as mucinous 
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cystadenoma NOS (Not otherwise specified). The summary of each subtype with 
their specific immunophenotype is shown in Table 9. 
In our study, the frequency of coexistence of MCT was relatively high, 
since 14/139 (10%) of the cases were in association with MCT. In contrast, the 
frequency of coexistence of BTs was less than MCT. Only one of the tumors in 
our study was in coexistence with BT. Our results showed a slight difference 
between those cases of MAs in association with MCT, and those with no 
association. The CLDN18 positivity was found in nearly all cases of MAs 
associated with MCT with one exceptional case. In contrast, CDX2 expression in 
MAs which coexisted with MCT was higher than those cases with no association. 
CDX2 positivity was found in 9/14 (65%) of MAs in association with MCT, 
while CDX2 positivity in MAs with no association with MCT was 31/125 (26%) 
(P=0.0109). This is consistent with the previous studies (15), suggesting that, 
MA associated with MCT exhibits immunohistochemical features similar to 
lower gastrointestinal type mucinous tumor.  
 
CLDN18 expression in benign ovarian lesions and Müllerian duct 
derivatives. 
CLDN18 expression in benign ovarian lesions and Müllerian duct 
derivatives are listed in Table 10. Among variety of benign-looking mucinous 
epithelium of the ovary, CLDN18 expression was demonstrated exclusively in 
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gastric-type mucinous epithelium in mature cystic teratomas, and metaplastic 
mucinous epithelium in (benign/borderline) Brenner tumors. In mature cystic 
teratomas, diffuse CLDN18 expression was observed in gastric foveolar 
epithelium, fundic glands, and pyloric glands, while intestinal (colonic) type 
mucinous epithelium containing goblet cells was always negative. Focal 
CLDN18 expression was seen in the metaplastic mucinous epithelium that lines 
the inner lumen of the transitional cell epithelium in two of three (2/3, 67%) 
benign/borderline Brenner tumors. The CLDN18 expression in benign 
teratomatous and metaplastic mucinous epithelium in BTs is shown in Figure 14.  
The epithelium that lined the ECs was CLDN18-negative in all cases 
(0/10). We evaluated CLDN18 expression in focal metaplastic mucinous 
epithelium in the cyst wall of ECs, which was also negative (0/5). Other ovarian 
lesions, such as surface epithelial inclusions (n=5) and serous cystadenomas 
(n=8), Müllerian duct derivatives that included fallopian tube epithelium (n=6), 
endometrial glands in different stages of the menstrual period (n=41), 
endocervical epithelium (n=6), and epithelium of endometriotic lesions (n=6), 
were all negative for CLDN18. 
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Discussion  
Mucinous cystadenomas are currently classified under ovarian epithelial 
tumors and account for 17% of all ovarian neoplasms. Controversy has 
surrounded the histogenesis of ovarian mucinous tumors. Several theories to 
describe the histogenesis of ovarian mucinous tumors have been previously 
suggested. Some researchers believe that, most ovarian mucinous tumors arise 
from surface epithelium. Some other investigators suggested that ovarian 
mucinous tumors are actually of teratomatous origin, since coexisting teratoma 
was found in 11% of ovarian mucinous tumors (15), while around 5% of 
teratomas were associated with mucinous cystadenoma or adenocarcinomas in 
the same ovary (16, 77). It is now generally accepted that some mucinous 
cystadenoma arise from gastrointestinal-type elements that exist in mature cystic 
teratoma (75). It has also been reported that an ovarian mucinous tumor can 
contain both components of surface epithelium, and teratomatous epithelium (68, 
69, 76).  
Another ovarian lesion that is currently believed to contribute to ovarian 
mucinous tumorigenesis is Brenner tumor. In a study by Waxman et al, 66 of 460 
Brenner tumors were associated with mucinous cystadenoma or rarely with 
adenocarcinoma (79). It is of note that epithelium of Brenner tumors have 
tendency to undergo mucinous metaplasia. In general, those mucinous tumors 
which are associated with Brenner tumors are thought to originate from areas of 
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mucinous metaplasia within transitional epithelium of Brenner tumors nests (80, 
81). Silverberg et al. showed a transition between the epithelium of mucinous 
cystadenoma and epithelium of the Brenner tumor (80). In addition to teratoma 
and Brenner tumor, mucinous tumors in association with sertoli-leydig cell 
tumors and granulosa cell tumor has also been previously reported (82-84). 
According to all these reports, the heterogeneous origin of ovarian mucinous 
tumor has gradually been accepted. However, the histogenetic relationship of 
gastrointestinal-type mucinous epithelium and Müllerian-type epithelium such as 
those of endometrial cysts in the ovary has not been clearly described in the past.  
In this study, our immunohistochemistry revealed that most of the MAs 
contained gastrointestinal-type mucinous epithelium which is characterized by 
CLDN18 and CDX2 expression. CLDN18-positivity in nearly all cases of MAs 
suggests that these tumors are part of the ovarian gastrointestinal-type tumor 
lineage. Since, they have similar immunophenotype with IMBTs and IMCas, we 
consider them as a benign counterpart or precursor lesion for ovarian IMBTs and 
IMCas. In addition the existence of CLDN18-positive mucinous epithelium in 
mature cystic teratomas and Brenner tumors, along with CLDN18/and or CDX2 
expression in nearly all MAs in association with mature cystic teratomas and 
Brenner tumor support the hypothesis that the origin of gastrointestinal-type 
mucinous neoplasms of the ovary maybe these lesions.  
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In this study, we succeeded in demonstrating the potential of Müllerian 
duct derivatives to bear gastrointestinal-type mucinous epithelium. In this study, 
in 12 cases (9%) of mucinous cystadenomas, we found an area of transition from 
Müllerian-type epithelium (CLDN18-/CDX2-/ER+) to gastrointestinal-type 
mucinous epithelium (CLDN18+/CDX2±/ER-). Interestingly in three of them, 
the tumors were in association with endometrial cyst. Transition from Müllerian-
type epithelium (CLDN18-/CDX2-/ER+) of ECs to gastric foveolar-type 
epithelium (CLDN18+/CDX2±/ER-) of MAs was observed (Figure 9 E, F).  
Furthermore, cases that showed mixed gastrointestinal/Müllerian 
phenotype were seen in 18 (14%) of MAs. Based on all these findings, we 
believe that a subset of gastrointestinal-type MA is derived from Müllerian duct 
derivatives, such as endometriosis. Surface epithelial inclusions and Müllerian-
type lesion such as serous cystadenomas assessed in our series were all negative 
for CLDN18. Müllerian duct derivatives such as endocervical epithelium, 
endometrium, and tubal epithelium were all negative for CLDN18. We believe 
that, gastrointestinal-type epithelium arise from Müllerian-type epithelium 
through metaplastic/neoplastic process.  
Another important observation was the existence of CLDN18-/CDX2-
/ER+ MAs. This has not been clearly defined in the past. The morphology of the 
mucinous epithelium of the cyst was closest to the Müllerian-type or 
endocervical-type mucinous epithelium seen in other lesions such as EMBTs. 
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The tumors showed no cytological atypia and minimal papillary growth. 
Therefore, we postulate that “Müllerian-type mucinous cystadenoma” would be 
the most appropriate diagnosis for those cases (Figure 13). Until now, there was 
no established subclassification of MAs. However, according to our findings, 
there are two different kinds of MAs, gastrointestinal and Müllerian 
(endocervical).  
 In summary, our results showed that mucinous cystadenomas can be 
subclassified into two major subtypes, gastrointestinal-type and Müllerian-type. 
Most of the mucinous cystadenomas show differentiation toward gastrointestinal-
type mucinous epithelium which characterized by CLDN18 and/or CDX2 
expression and negative immunoreactivity for ER. These tumors are considered 
as a benign counterpart of ovarian gastrointestinal-type mucinous tumor lineage. 
They have similar immunophenotype with IMBTs and IMCas and considered to 
be a precursor lesion for these tumors. Since the transition from Müllerian-type 
epithelium to gastrointestinal-type mucinous epithelium is seen in some of our 
cases, we conclude that gastrointestinal-type epithelium in the ovary can arise not 
only from teratomatous lesions or Brenner tumors but also from Müllerian duct 
derivatives (Figure 15). 
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Final conclusions: 
The results of this study showed that: 
1. Intestinal-type and endocervical-type ovarian mucinous tumors are two 
distinct entities with completely different immunophenotype. 
2. We can accurately and easily distinguish intestinal-type and endocervical-
type ovarian mucinous tumors by using CLDN18 immunohistochemistry. 
3. Our results showed that, lesions which have been conventionally regarded 
as intestinal-type tumors are essentially of gastrointestinal-type. Since, the 
predominant components are usually gastric-type epithelium, rather than 
intestinal-type.  
4. IMCa share similar immunophenotype with IMBTs and is considered to 
be a malignant subtype of ovarian gastrointestinal-type mucinous tumor 
category. 
5. In this study, we showed the utility of CLDN18 immunohistochemistry in 
distinction between IMCas, and non-mucinous ovarian adenocarcinomas, 
and also between IMCas and metastatic CRCs involving the ovary, which 
is clinically significant. 
6. We also showed that mucinous cystadenomas consist of two different 
subtypes. The majority of which is gastrointestinal-type characterized by 
CLDN18+/CDX2±/ER- immunophenotype. Müllerian-type MAs which 
characterized by CLDN18-/CDX2-/ER+ immunophenotype is rather rare. 
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7. Mucinous cystadenomas show similar immunophenotype with IMBTs and 
IMCas and are considered as a benign counterpart and precursor lesion for 
IMBTs and IMCas. 
8. In addition to, MCT and BTs, we found some evidence that a subsets of 
gastrointestinal-type mucinous ovarian tumors originate form Müllerian 
duct derivatives such as endometriosis.  
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Table 1.  
Antibodies used for immunohistochemistry:  
 
Antibody Dilution Clone Manufacturer 
CLDN18 1:1000 Poly Zymed 
MUC1 1:100 MA695 Novocastra 
MUC2 1:20 Ccp58 Novocastra 
MUC5AC 1:100 CLH2 Novocastra 
MUC6 1:100 CLH5 Novocastra 
CDX2 1:200 CDX2-88 Cell Marque 
CK7 1:100 OV-TL12/30 DakoCytomation 
CK20 1:100 Ks 20.8 Novocastra 
ER Prediluted ER1D5 Ventana 
PgR Prediluted A9621A Ventana 
CA125 1:200 Ov 185:1 Novocastra 
Vimentin 1:1000 V9 DakoCytomation 
CLDN18, claudin-18; CK7, cytokeratin 7; CK20, cytokeratin 20; ER, estrogen receptor; 
PgR, progesterone receptor. 
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Table 2. 
Claudin-18, MUCs, and CDX2 expression in intestinal-type and endocervical-like 
mucinous borderline tumors:  
 
 
 CLDN18 MUC1 MUC2 MUC5AC MUC6 CDX2 
 IMBT EMBT IMBT EMBT IMBT EMBT IMBT EMBT IMBT EMBT IMBT EMBT 
- 1 24 30 0 36 24 4 7 42 19 28 25 
1+ 0 0 9 3 9 1 2 5 6 2 12 0 
2+ 1 1 7 4 6 0 5 9 5 4 7 0 
3+ 4 0 5 5 3 0 9 3 1 0 6 0 
4+ 48 0 3 13 0 0 34 1 0 0 1 0 
Total 53/54 
(98%) 
1/25 
(4%) 
24/54 
(44%) 
25/25 
(100%) 
18/54 
(33%) 
1/25 
(4%) 
50/54 
(93%) 
18/25 
(72%) 
12/54 
(22%) 
6/25 
(24%) 
26/54 
(48%) 
0/25 
(0%) 
P <0.0001 <0.0001 0.0042 0.0307 >0.9999 <0.0001 
 
IMBT (Intestinal-type mucinous borderline tumor) 
EMBT (Endocervical-type mucinous borderline tumor)  
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Table 3. 
Expression of cytokeratins and Müllerian markers in intestinal-type and 
endocervical-like mucinous borderline tumors. 
 
 
 CK7 CK20 ER PgR CA125 Vimentin 
 IMBT EMBT IMBT EMBT IMBT EMBT IMBT EMBT IMBT EMBT IMBT EMBT 
- 0 0 11 24 52 0 53 5 35 0 53 0 
1+ 1 0 9 1 0 0 0 1 10 0 1 1 
2+ 2 0 10 0 2 0 1 6 4 0 0 2 
3+ 3 1 15 0 0 1 0 8 4 0 0 9 
4+ 48 24 9 0 0 24 0 5 1 25 0 13 
Total 54/54 
(100%) 
25/25 
(100%) 
43/54 
(80%) 
1/25 
(4%) 
2/54 
(4%) 
25/25 
(100%) 
1/54 
(2%) 
20/25 
(80%) 
19/54 
(35%) 
25/25 
(100%) 
1/54 
(2%) 
25/25 
(100%) 
P >0.0999 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
 
IMBT (Intestinal-type mucinous borderline tumor) 
EMBT (Endocervical-type mucinous borderline tumor)  
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Table 4. 
Immunophenotype of serous borderline tumors:  
 
 CLDN18 MUC1 MUC2 MUC5AC MUC6 CDX2 CK7 CK20 ER PgR CA125 Vimentin 
- 22 0 22 21 22 22 0 22 0 1 0 0 
1+ 0 0 0 1 0 0 0 0 0 1 0 2 
2+ 0 0 0 0 0 0 0 0 0 0 0 0 
3+ 0 0 0 0 0 0 1 0 0 3 0 3 
4+ 0 22 0 0 0 0 21 0 22 17 22 17 
Total 
0/22 
(0%) 
22/22 
(100%) 
0/22 
(0%) 
1/22 
(5%) 
0/22 
(0%) 
0/22 
(0%) 
22/22 
(100%) 
0/22 
(0%)  
22/22 
(100%) 
21/22 
(95%) 
22/22 
(100%) 
22/22 
(100%) 
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Table 5. 
Summary of primary IMCas, and metastatic CRCs involving the ovary according 
to the tumor size and laterality:  
   Primary IMCa Metastatic CRC 
Laterality 
Unilateral 17/19 (90%) 9/16 (56%) 
Bilateral 2/19 (10%) 7/16 (44%) 
Tumor size 
≥10cm 17/19 (90%) 11/16 (69%) 
<10cm 2/19 (10%) 4/16 (25%) 
IMCas (Intestinal-type mucinous adenocarcinomas) 
CRCs (colorectal adenocarcinoma). 
Summary of metastatic colorectal carcinomas (CRCs) involving the ovary based on 
their laterality and size: 
 Tumors <10cm Tumors ≥10cm 
Unilateral 0 3* 
Bilateral 4 8 
*The 3 cases (unilateral ≥10cm) which have been consistent with the algorithm. 
 
Summary of primary Intestinal-type mucinous adenocarcinomas (IMCas) based on their 
laterality and size: 
 Tumors <10cm Tumors ≥10cm 
Unilateral 2 15 
Bilateral 0 2 
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Table 6. 
CLDN18 immunohistochemistry among variety of ovarian mucinous, and non-
mucinous adenocarcinomas. 
 
Type of carcinomas CLDN18 expression P. value 
Intestinal type mucinous carcinoma (IMCa) 11/12 (92%)  
Endometrioid adenocarcinoma (EMCa) 3/38 (6%)  
High grade serous carcinoma (HGSCa) 0/58 (0%) <0.0001  
Low grade serous carcinoma (LGSCa) 0/11 (0%)  
Clear cell adenocarcinoma  (CCCa) 0/95 (0%)  
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Table 7.  
Immunohistochemical comparison between primary IMCas, and metastatic CRCs 
involving the ovary.  
 
 
IMCas (Intestinal-type mucinous adenocarcinomas) 
CRCs (colorectal adenocarcinoma).
 CK7 CK20 CDX2 MUC2 MUC5AC CLDN18 ER 
 IMCas CRCs IMCas CRCs IMCas CRCs IMCas CRCs IMCas CRCs IMCas CRCs IMCas CRCs 
0 0 14 5 0 5 0 12 2 3 13 3 14 18 16 
1+ 0 1 4 2 2 0 5 4 4 3 1 1 0 0 
2+ 1 0 3 2 5 0 1 8 5 0 3 1 0 0 
3+ 2 1 6 9 5 0 0 0 5 0 4 0 1 0 
4+ 16 0 1 3 2 16 1 2 2 0 8 0 0 0 
Total 19/19 
(100%) 
2/16 
(12%) 
14/19 
(74%) 
16/16 
(100%) 
14/19 
(74%) 
16/16 
(100%) 
7/19 
(37%) 
14/16 
(87%) 
16/19 
(84%) 
3/16 
(19%) 
16/19 
(85%) 
2/16 
(12%) 
1/19 
(5%) 
0/16 
(0%) 
P <0.0001 0.057 0.0473 0.0022 0.0001 <0.0001 0.9999 
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Table 8. 
CLDN18, CDX2, and ER expression in ovarian mucinous cystadenoma:  
 CLDN18 CDX2 ER 
- 12 99 101 
1+   3 16 11 
2+  6 10 8 
3+  29 11 6 
4+  89 3 13 
 
 
127/139  
(91%) 
40/139  
(29%) 
38/139  
(27%) 
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Table 9. IHC results in mucinous cystadenoma  
Expression of CLDN18, CDX2 and ER in mucinous cystadenomas according to their specific phenotypes 
G
ro
u
p
s 
Tumors specific categories Immunoexpression 
T
o
ta
l 
ca
se
s 
IHC results on 
representative section 
Coexisting lesions 
CLDN1
8 
CDX2 ER MCT Brenner EM cyst 
Endomet
riosis 
A 
Pure GI-type MAs 
CLDN18+/CDX2+/ER- 
99 
97/97 28/97 0/97 13 1 2 1 
CLDN18-/CDX2+/ER- 0/2 2/2 0/2 0 0 0 0 
Pure GI-type MAs (CLDN18+/CDX2±/ER-) in transition from 
M-type epithelium (CLDN18-/CDX2-/ER+). 
(The predominant components in the tumors was GI-type epithelium) 
12 12/12 5/12 12/12 0 0 3 0 
B MAs with Mixed phenotypes (CLDN18+/CDX2±/ER+) 18 18/18 5/18 18/18 1 0 0 1 
C Pure Müllerian-type MAs CLDN18-/CDX2-/ER+ 8 0/8 0/8 8/8 0 0 1 0 
D NOS (non-specific-type MAs) CLDN18-/CDX2-/ER- 2 0/2 0/2 0/2 0 0 0 0 
GI-type MAs: gastrointestinal-type mucinous cystadenomas. M-type: Müllerian-type 
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Table 10.  
CLDN18 expression in benign ovarian mucinous lesions and non-neoplastic mullerian 
duct derivatives:  
 
Type of lesions         CLDN18 positivity 
Mucinous cystadenoma (MA)  
MA with no association with MCT or EC  107/116 
MA in association with MCT   13/14  
MA in transition with EC    3/3 
MA in coexistence with EC    1/3 
MA in association with endometriosis  2/2 
MA in association with BT    1/1 
Gastric-type mucinous epithelium in MCT   5/6 
Colonic-type mucinous epithelium in MCT  0/7 
ECs without mucinous metaplasia              0/10 
Metaplastic mucinous epithelium in EC                 0/5 
Metaplastic mucinous epithelium in BT   2/3 
Surface epithelial inclusion    0/5 
Serous cystadenoma      0/8 
Fallopian tube epithelium    0/6 
Endometrial epithelium     0/41 
Endocervical epithelium    0/6 
Endometriosis       0/6 
 
MCT (mature cystic teratoma), EC (endometrial cyst), BT (brenner tumor). 
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Figure 1. (A) Representative histology of intestinal-type mucinous borderline tumor. (B) Diffuse 
membranous expression of CLDN18 in intestinal-type mucinous borderline tumor. (C) CLDN18 
expression in gastric foveolar-type mucinous epithelium of intestinal-type mucinous borderline tumor. 
Diffuse basolateral staining is observed in the Goblet cell-rich area of the intestinal-type mucinous 
borderline tumor. (D) CLDN18-positivity is observed in the majority of the tumor cells. (E) 
Representative histology of endocervical-like mucinous borderline tumor characterized by prominent 
papillary structures and stromal inflammation. (F) CLDN18 is completely negative in an endocervical-like 
mucinous borderline tumor. 
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Figure 2. Expression of MUC2, MUC5AC, and CDX2 in (A, C, E) intestinal-type mucinous borderline tumor 
and (B, D, F) endocervical-like borderline tumor. (A) Focal MUC2 expression in a goblet cell-rich 
intestinal-type mucinous borderline tumor. (B) Endocervical-like borderline tumor negative for MUC2. 
(C) Diffuse MUC5AC expression in intestinal-type mucinous borderline tumor. (D) MUC5AC expression in 
endocervical-like mucinous borderline tumors is often focal. (E) Patchy and focal CDX2 positivity in 
intestinal-type mucinous borderline tumors. (F) CDX2 is always negative in endocervical-like mucinous 
borderline tumors. 
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Figure 3. Expression of CK20, ER, and vimentin in (A, C, E) intestinal-type mucinous borderline tumors 
and (B, D, F) endocervical-like borderline tumors. (A) Intestinal-type mucinous borderline tumor showing 
strong CK20 expression. (B) CK20 is negative in endocervical-like mucinous borderline tumors. (C) ER is 
usually negative in intestinal-type mucinous borderline tumors, while (D) endocervical-like mucinous 
borderline tumors always shows diffuse and strong nuclear positivity. (E) Vimentin expression is seen 
only in the stroma of intestinal-type mucinous borderline tumors. The tumor cells are vimentin-negative. 
(F) Vimentin expression in an endocervical-like mucinous borderline tumor. Many of the tumor cells 
show positive immunoreactivity along with stromal cells. 
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Figure 4. Unsupervised two-way hierarchical clustering based on the protein expression 
of ovarian borderline tumors. Intestinal-type mucinous borderline tumors were grouped 
separately from endocervical-like and serous borderline tumors. Similarities between 
the immunoprofiles of endocervical-like borderline tumors and serous borderline 
tumors are demonstrated. 
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Figure 5. (A) Representative 
histology of IMCa. CLDN18 is 
diffusely positive in IMCas (B). 
 
 
(C) Representative histology of 
HGSCa. CLDN18 is always 
negative in HGSCa (D). 
 
(E) Representative histology of 
LGSCa. CLDN18 is always 
negative in LGSCa (F) 
 
(G) Representative histology of 
CCCa HE. CLDN18 is always 
negative in CCCa (H) 
 
 
(I) Representative histology of 
EMCa HE. CLDN18 is negative 
in nearly all EMCas (J). 
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Figure 6. CLDN18 expression in primary IMCa and Metastatic CRC involving the ovary. 
(A) Representative histology of primary IMCa. (B) CLDN18 is usually positive in primary 
IMCa. (C) Metastatic CRC involving the ovary HE. (D) Metastatic CRC involving the ovary 
is usually CLDN18 negative. 
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Figure 7. MUC5AC and CK7 expression in primary IMCa and metastatic CRC involving the 
ovary. (A) MUC5AC is focally positive in majority of primary IMCas. (B) Metastatic CRC 
involving the ovary is almost always CLDN18 negative. (C) Primary IMCa is diffusely 
positive for CK7. (D) CK7 is always negative in metastatic CRC involving the ovary.  
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Figure8. Expression of CK20 and CDX2 in primary IMCa and metastatic CRC involving 
the ovary. (A) CK20 is focally expressed in primary IMCa, while it expression in 
metastatic CRC is usually diffuse (B). CDX2 expression in primary IMCa is focal and weak 
(C). In contrast to IMCas, CDX2 expression in metastatic CRC is usually diffused and 
strong (D).  
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Figure 9. Gastrointestinal-type mucinous cystadenoma. (A) Representative histology of gastrointestinal-
type mucinous cystadenoma composed of gastric foveolar-type epithelium. (B) Tumor shows diffused 
basolateral membranous staining for CLDN18. (C) ER is usually negative in gastrointestinal-type MAs. (D) 
CDX2 expression is often negative in MAs. (E) Gastrointestinal-type mucinous cystadenoma, that showed 
transition from endometrial cyst (inset), and (F) its CLDN18 expression. The mucinous cystadenoma 
expresses CLDN18 diffusely, whereas the epithelium of the background endometrial cyst is negative.  
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Figure 10. Gastrointestinal-type mucinous cystadenoma.(A) Representative histology of 
gastrointestinal-type mucinous cystadenoma composed of gastric foveolar-type 
epithelium. (B) Tumor shows diffused basolateral membranous staining for CLDN18. (C) 
ER is usually negative. (D) CDX2 expression is focally observed in some cases.  
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Figure 11. Gastrointestinal-type mucinous epithelium showing transition from 
Müllerian-type epithelium (A). CLDN18 expression is negative in areas with Müllerian-
type epithelium, positive for areas with gastrointestinal-type epithelium (B). Diffused 
nuclear staining for ER is seen in areas with Müllerian-type epithelium, while ER 
expression is gradually losing in area with gastrointestinal-type epithelium (C). CDX2 
expression is completely negative in both types of epithelium (D). 
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Figure12. Mucinous cystadenoma with mixed phenotypes (gastrointestinal and 
Müllerian). Representative histology (A). CLDN18 is diffusely positive in the tumor cells 
(B). Diffused nuclear staining for ER is also observed in morphologically gastrointestinal-
type mucinous epithelium (C). CDX2 is completely negative (D).  
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Figure 13. Müllerian-type mucinous cystadenoma representative histology (A). CLDN18 
is always negative in Müllerian-type MAs (B). Diffused nuclear staining for ER is seen in   
Müllerian-type MA(C). CDX2 expression is completely negative (D). 
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Figure 14.   
CLDN18 expression in mucinous epithelium 
of  teratoma and Brenner tumor. (A) Diffuse 
CLDN18 expression in gastric-type mucinous 
epithelium in mature cystic teratoma. (B) 
Colonic-type epithelium in mature cystic 
teratoma is negative for CLDN18. (C) 
Metaplastic mucinous epithelium in a 
Brenner tumor showing focal CLDN18 
expression. 
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Figure 15. 
Schematic demonstration of ovarian mucinous tumorigenesis 
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